Post Tagged with: "Alzheimer’s disease"

Lee-Colvin Collaboration Results in NIH Funding to Study Alzheimer’s Disease

Lee-Colvin Collaboration Results in NIH Funding to Study Alzheimer’s Disease

Long-standing research collaboration between Drs. Daewoo Lee and Robert Colvin has resulted in National Institutes of Health funding to study Alzheimer’s disease. Lee and Colvin were always exchanging ideas as they crossed paths in the hallways of the Life Sciences Building. Now they are collaborating in their labs in search […]

Read more ›
January 5, 2021 at 12:51 pmResearch

Colvin Reports on Novel Kinase Inhibitors, Target for Therapeutic Development in Alzheimer’s

Colvin Reports on Novel Kinase Inhibitors, Target for Therapeutic Development in Alzheimer’s

Dr. Robert Colvin, Professor and Chair of Biological Sciences at Ohio University, presented at a conference on “Thinking Outside the ATP Box: New ways to Target Kinases for Therapeutics,” which brought together top researchers in the field to explore and discuss cutting-edge research and challenges to developing highly specific inhibitors […]

Read more ›
May 31, 2018 at 5:01 pmResearch

Yavorsky Presents on Alzheimer’s Disease at the Ohio Osteopathic Symposium

Yavorsky Presents on Alzheimer’s Disease at the Ohio Osteopathic Symposium

Ryan Yavorsky presented research on tau protein and its role in the pathogenesis of Alzheimer’s disease at the Ohio Osteopathic Symposium held April 27 in Columbus. Yavorsky is a second-year medical student in Ohio University’s Heritage College of Osteopathic Medicine and has worked in the lab of Dr. Robert Colvin, […]

Read more ›
May 2, 2018 at 12:32 pmResearch

NIH Supports Goetz Team to Study Novel Therapeutic

Model of Tideglusib bound to a kinase (GSK3) associated with medical disorders such as Alzheimer's disease and cancer (image courtesy of J. V. Hines).

By Amanda Biederman NQPI editorial intern Douglas Goetz, Chemical and Biomolecular Engineering Professor, Molecular and Cellular Biology Faculty and Nanoscale & Quantum Phenomena Institute member, and Ohio University colleagues were recently awarded a grant from the National Institutes of Health to characterize an inhibitor of glycogen synthase kinase 3 (GSK3), […]

Read more ›
May 14, 2017 at 9:14 pmNews